Document Detail


Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?
MedLine Citation:
PMID:  18380646     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To investigate the impact of adopting pharmaceutical innovations on the growth of pharmaceutical expenditures, focusing specifically on Taiwan's experience. METHODS: We first provide a descriptive analysis of cost impacts of introducing new drugs into Taiwan's national formulary using data from Taiwan. We then use a statistical method to decompose the growth of pharmaceutical expenditures during 1997-2001 into three components: 1) treatment expansion; 2) treatment substitution; and 3) price effect. By incorporating the estimated benefit from prior studies, we calculate the incremental cost-effectiveness ratio for new drugs as a whole. RESULTS: We find that from 1997 to 2001 public expenditures on pharmaceuticals grew 57%. The primary drivers of this expenditure growth were treatment expansion and treatment substitution. Prices declined by 18%. Cost per life-year gained resulting from introduction of new drugs was US$1053 (in 2003 dollars) from the perspective of the public payer and US$1824 from the perspective of society as a whole. CONCLUSIONS: Overall, our analysis provides evidence with previous studies that the drug reimbursement price is not the primary driver of increased spending. Rather the introduction of new drugs into the formulary leading to expansion of treatment, expansion and substitution of the new drugs for existing drugs may increase spending. Although the adoption of pharmaceutical innovation is costly, the estimated benefit of adopting pharmaceutical innovation generally far exceeds the cost, indicating that the adoption of pharmaceutical innovation is on the whole worthwhile.
Authors:
Chee-Ruey Hsieh; Frank A Sloan
Related Documents :
10169666 - Cost-related information to be provided by computerised drug-prescription systems to pr...
16117996 - Caspofungin versus amphotericin b for candidemia: a pharmacoeconomic analysis.
10146976 - Pharmacoeconomic consequences of measurement and modification of hospital drug use.
16777256 - Reference drug programs: effectiveness and policy implications.
9878826 - Hypericum li 160 inhibits uptake of serotonin and norepinephrine in astrocytes.
12385816 - The long-term effects of nefiracetam on learning in older rabbits.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research     Volume:  11     ISSN:  1524-4733     ISO Abbreviation:  Value Health     Publication Date:    2008 Mar-Apr
Date Detail:
Created Date:  2008-04-02     Completed Date:  2008-04-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883818     Medline TA:  Value Health     Country:  United States    
Other Details:
Languages:  eng     Pagination:  334-44     Citation Subset:  IM    
Affiliation:
The Institute of Economics, Academia Sinica, Taipei, Taiwan. crh@econ.sinica.edu.tw
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cost-Benefit Analysis
Diffusion of Innovation*
Drug Costs*
Drug Utilization / economics
Health Expenditures / statistics & numerical data
Humans
National Health Programs / economics*
Pharmacopoeias as Topic*
Physician's Practice Patterns / economics*
Taiwan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: ...
Next Document:  Vector transmission of Bartonella species with emphasis on the potential for tick transmission.